Updated on 29 Dec 2017
Your place to Learn and Earn
Disclaimer: Information presented on this site is a guide only. It may not necessarily be correct and is not intended to be taken as financial advice nor has it been prepared with regard to the individual investment needs and objectives or financial situation of any particular person. Stock quotes are believed to be accurate and correctly dated, but www.stockmarketindian.com does not warrant or guarantee their accuracy or date.
www.stockmarketindian.com takes no responsibility for any investment decisions based on recommendations provided on website.
Financial contents like Technical charts, historical charts and quotes are taken from NSE and Yahoo sites.
Note - All quotes are delayed by 15 minutes and unless specified.

Google Adsense Ads are posted on every page of the website so visitors clicking on Ads and going to those links and carrying any financial deal is not at all related to www.stockmarketindian.com and any financial deal should be done on their own sole responsibility.
Please read our before using any material or advice given at www.stockmarketindian.com

These ten large cap stocks were in negative in returns
Latest posts
These ten large cap stocks were in negative in returns
With the benchmark equity indices soaring all-time high levels, and market capitalisation of BSE-listed companies touching Rs 150 lakh crore-mark.

BSE's largecap benchmark Sensex is up 27 per cent for the ongoing calendar, but these 10 stocks have fallen up to 41 per cent and they collectively lost Rs 1.2 lakh crore of market capitalisation in the year that is drawing to a close.

Data showed shares of Lupin have tumbled over 41 per cent this year. The drug maker's m-cap has fallen from about Rs 67,000 crore last year to Rs 39,700-odd crore. Glenmark (down 37 per cent), Dr Reddy's Labs (down 23 per cent) and and Sun Pharma (down 16 per cent) are other worst performing BSE100 stocks this calendar.

Frontline pharma players, those commanding more than $500 million in US sales, have been left beaten and bruised over the past 12‐18 months. The key reasons behind the accentuated decline in US sales are well known by now: generic price erosion, faster FDA approvals and large portfolios roiled by channel consolidation.

Among other players, Tata Motors (down 11 per cent) and its DVRs (down 21 per cent) too disappointed Dalal Street during the year. The automaker reported 14 per cent drop in profit after tax (PAT) annually over FY12-17 on a 10 per cent compounded annual growth rate in sales during the same period and this could be one of the reason for this fall.

Among other stocks, Coal India dropped 11 per cent this calendar. IDFC Bank is down 8 per cent , Bosch 5 per cent and ONGC 2 per cent, respectively.